The Teduglutide (the Gattex brand name in the US and Revestif in Europe) is a 33 member polypeptide and glucagon-like peptide-2 (GLP-2 ) analogues used for the treatment of short bowel syndrome. It works by promoting mucosal growth and may restore gastric emptying and secretion. In Europe has been given orphan drug status and marketed under the brand Revestive by Nycomed. It was approved by the United States under the name Gattex on December 21, 2012 and is also an orphan drug there.
Video Teduglutide
Medical use
Up to a point, the gut can adapt to partial resections that produce short bowel syndrome. However, parenteral replacement of water, minerals and vitamins (depending on which part of the intestine has been removed) is often necessary. Teduglutide can reduce or shorten the need for the infusion by improving the intestinal mucosa and possibly by other mechanisms.
Maps Teduglutide
Adverse effects
Common side-effects in clinical studies included abdominal discomfort (49% of patients), respiratory infections (28%), nausea (27%) and vomiting (14%), local reactions at the injection site (21%), and headache %).
Chemical and action mechanism
Teduglutide differs from natural GLP-2 by a single amino acid: alanine is replaced with glycine. This blocks the breakdown of the molecule with dipeptidyl peptidase and increases the half-life of seven minutes (GLP-2) to about two hours, while retaining its biological action. These include the maintenance of intestinal mucosa, increased intestinal blood flow, reduced gastrointestinal motility and gastric acid secretion.
References
Source of the article : Wikipedia
0 Comments